Cholangiocarcinoma (Bile Duct Cancer)

Cholangiocarcinoma (CCA) is the medical term for bile duct cancer — a malignancy arising from the epithelial cells lining the bile ducts. In clinical and specialist settings, the term cholangiocarcinoma is used to encompass all anatomical subtypes: intrahepatic (arising inside the liver), perihilar (at the bile duct junction — the Klatskin tumour), and distal (in the lower common bile duct). Lay audiences often use 'bile duct cancer', while clinicians use 'cholangiocarcinoma'. The term 'CCA' is the clinical abbreviation used in oncology, haematology, and research contexts.

FGFR2 gene fusions are structural DNA rearrangements — not point mutations — where part of the FGFR2 gene joins with another gene (the fusion partner, e.g. BICC1, CASC15, or others). The resulting fusion protein has constitutively active FGFR2 kinase signalling, driving tumour cell survival and proliferation. FGFR2 fusions are present in approximately 13–15% of intrahepatic cholangiocarcinoma. Two approved FGFR2 inhibitors — pemigatinib and futibatinib — specifically target this fusion protein and have demonstrated meaningful tumour response rates in this subgroup. Importantly, FGFR2 fusions are structural rearrangements that are NOT detected by standard DNA hotspot mutation panels; RNA-based or structural variant-aware NGS panels are required.

IDH1 (isocitrate dehydrogenase 1) R132 mutations are gain-of-function point mutations that cause the IDH1 enzyme to produce an oncometabolite called 2-hydroxyglutarate (2-HG). 2-HG inhibits enzymes that regulate DNA and histone methylation, causing widespread epigenetic dysregulation and blocking normal cell differentiation. IDH1 R132 mutations are present in approximately 15–20% of intrahepatic cholangiocarcinoma. Ivosidenib (Tibsovo) is an approved oral IDH1 inhibitor that blocks mutant IDH1 and reduces 2-HG levels, restoring more normal epigenetic control. IDH1 mutations are identified by NGS or IDH1-specific PCR assays; they are point mutations detectable by standard NGS, unlike FGFR2 fusions.

Molecular profiling in cholangiocarcinoma requires an NGS panel that can detect all of the following: gene fusions and structural variants (for FGFR2, NTRK), point mutations (IDH1, KRAS, TP53, BRAF), copy number alterations (HER2 amplification), and MSI/TMB status. The critical technical requirement is that the panel must detect structural variants — not just mutations. An RNA-based NGS or a DNA panel with structural variant calling capability is needed; a standard hotspot mutation panel will miss FGFR2 fusions. When speaking with your oncologist, ask: 'Has the NGS panel been designed to detect FGFR2 fusions, or is it a mutation-only panel?'

The current standard first-line treatment for advanced or unresectable cholangiocarcinoma is gemcitabine plus cisplatin (GemCis) combined with an immune checkpoint inhibitor — either durvalumab (based on the TOPAZ-1 trial) or pembrolizumab (KEYNOTE-966 trial). This triplet combination has improved survival compared to GemCis alone and is now the preferred first-line regimen for patients with good performance status. MSI-H cholangiocarcinoma patients may derive particular benefit from the immunotherapy component. Carboplatin may substitute cisplatin for patients with renal impairment.

This is where molecular profiling results determine your options. If FGFR2 fusion-positive: pemigatinib or futibatinib are approved and should be the first consideration. If IDH1 R132-mutant: ivosidenib is approved. If NTRK fusion-positive: larotrectinib or entrectinib. If BRAF V600E: dabrafenib + trametinib. If HER2-positive: clinical trial access (zanidatamab, T-DXd) is the primary route. If no actionable alteration: FOLFOX-based chemotherapy (ABC-06 trial) is the standard second-line option. This is also when clinical trial eligibility should be formally assessed.

Complete surgical resection offers the only realistic chance of long-term disease control, with approximately 25–40% 5-year survival after R0 resection in selected patients. However, only around 30% of patients are resectable at diagnosis. For patients with advanced or metastatic disease, the goal of treatment shifts to maximising remission duration, maintaining quality of life, and matching therapy to molecular subtype. Molecularly targeted therapies (FGFR inhibitors, ivosidenib) produce durable responses in defined subgroups, and some patients achieve long-term partial or complete responses — but the term 'cure' is not applicable for advanced cholangiocarcinoma under current treatment paradigms.

Yes — cholangiocarcinoma is one of the most active areas for clinical trials in GI oncology. Current trials include next-generation FGFR2-selective inhibitors for post-pemigatinib/futibatinib resistance (lirafugratinib/RLY-4008), HER2-directed antibody-drug conjugates (zanidatamab, T-DXd), IDH1 inhibitor combination strategies, KRAS-directed therapies, and precision basket trials for rare molecular alterations. Patients with FGFR2 fusion-positive, IDH1-mutant, HER2-amplified, or KRAS-mutant CCA — and those who have progressed after approved targeted therapies — are among the most relevant trial candidates.

Yes. CancerFax supports cholangiocarcinoma patients in several ways: reviewing NGS molecular profiling results to confirm whether FGFR2 fusion testing was performed with the correct assay; coordinating specialist second opinions from hepatobiliary molecular oncologists; and facilitating access to approved targeted therapies including pemigatinib, futibatinib, and ivosidenib at specialist centres in China and globally where these agents may not be locally available or reimbursed.

For patients with HER2+ disease, NTRK fusions, or other rare molecular features, CancerFax can identify active trials and coordinate trial eligibility assessment. For patients in countries where approved agents are not locally accessible, CancerFax coordinates international treatment pathways through specialist oncology networks.